Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing ...
Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...
A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...
GlobalData on MSN5d
Health Canada issues NOC to J&J’s CARVYKTI for multiple myelomaThe study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...
Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...
Zacks.com on MSN1d
FDA Accepts GSK's BLA for Blenrep Combos in Multiple MyelomaThe FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
clinicaltrialsarena on MSN12d
GSK reports positive outcomes from Phase III multiple myeloma treatment trialGSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback